LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of Mircera when administered once
monthly, subcutaneously or intravenously, for the maintenance of hemoglobin levels in
dialysis patients with chronic renal anemia. Patients currently receiving maintenance
treatment with epoetin alfa will receive monthly injections of Mircera with a starting dose
(120, 200 or 360 micrograms) derived from the dose of epoetin alfa they were receiving in the
week preceding study start. The anticipated time on study treatment is 3-12 months, and the
target sample size is 100-500 individuals.